Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Glofitamab (Columvi, Roche) 'as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), after two or more lines of systemic therapy'.

The dosage schedule is available in the summary of product characteristics for glofitamab.

The list price for glofitamab is £687 per 2.5 mg vial and £2,748 per 10 mg vial (excluding VAT; company submission). An average course of glofitamab treatment per person, based on 5 cycles, is £46,536 including £3,312 for obinutuzumab pre-treatment (excluding VAT; company submission).

The company has a commercial arrangement. This makes glofitamab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.